Vigil Neuroscience, Inc.
VIGLDelisted Aug 5, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001827087
Vigil Neuroscience, Inc. was delisted on Aug 5, 2025; its insiders filed their last Form 4 on Aug 7, 2025; 78 institutions reported holding it in 13F filings for Q2 2025, worth $265.8M in total; no superinvestor held it.
13F holders, Q4 2022
Institutional positions in Vigil Neuroscience, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 37
- +4 vs. Q3 2022
- Shares held
- 25.0M
- +429.2K (+1.7%) vs. Q3 2022
- Total value
- $312.3M
- +$89.6M (+40.2%) vs. Q3 2022
- New holders
- 9
- 12 more added
- Sold out
- 5
- 7 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VIGL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 2 | $4.55K |
| Q2 2025 | 78 | $265.8M |
| Q1 2025 | 50 | $44.5M |
| Q4 2024 | 51 | $38.4M |
| Q3 2024 | 52 | $94.2M |
| Q2 2024 | 58 | $104.5M |
| Q1 2024 | 54 | $90.5M |
| Q4 2023 | 46 | $84.4M |
| Q3 2023 | 45 | $137.7M |
| Q2 2023 | 47 | $242.1M |
| Q1 2023 | 41 | $245.4M |
| Q4 2022 | 37 | $312.3M |
| Q3 2022 | 33 | $222.7M |
| Q2 2022 | 35 | $44.6M |
| Q1 2022 | 47 | $125.1M |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Vigil Neuroscience, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 85 | $1.06K | 0.00% | +31+57.4% | Added |
| State of Wyoming | 104 | $1.30K | 0.00% | +58+126.1% | Added |
| UBS Group AG | 510 | $6.38K | 0.00% | +510 | New |
| Tower Research Capital LLC (TRC) | 1,832 | $23.0K | 0.00% | +1,832 | New |
| Cannell Capital LLC | 8,044 | $100.5K | 0.02% | 00.0% | Unchanged |
| Morgan Stanley | 9,092 | $113.7K | 0.00% | +8,962+6,893.8% | Added |
| Bank of America Corp | 9,896 | $123.7K | 0.00% | +9,896 | New |
| 683 Capital Management, LLC | 15,092 | $188.7K | 0.02% | +15,092 | New |
| Northern Trust Corp | 18,794 | $234.9K | 0.00% | +6,712+55.6% | Added |
| Susquehanna International Group, LLP | 27,375 | $342.2K | 0.00% | +27,375 | New |
| State Street Corp | 35,739 | $446.7K | 0.00% | +14,365+67.2% | Added |
| Bank of Montreal | 58,100 | $726.3K | 0.00% | +58,100 | New |
| Goldman Sachs Group Inc | 73,011 | $912.6K | 0.00% | −130.0% | Reduced |
| FMR LLC | 86,650 | $1.08M | 0.00% | +59,695+221.5% | Added |
| Citigroup Inc | 93,927 | $1.17M | 0.00% | +26,272+38.8% | Added |
| BlackRock Inc. | 102,391 | $1.28M | 0.00% | +666+0.7% | Added |
| Geode Capital Management, LLC | 103,767 | $1.30M | 0.00% | +31,948+44.5% | Added |
| Barclays PLC | 105,893 | $1.32M | 0.00% | +3,730+3.7% | Added |
| Laurion Capital Management LP | 130,200 | $1.63M | 0.05% | 00.0% | Unchanged |
| DAFNA Capital Management LLC | 168,846 | $2.11M | 0.59% | −47,549−22.0% | Reduced |
| Logos Global Management LP | 188,390 | $2.35M | 0.28% | −17,205−8.4% | Reduced |
| Trustees of Columbia University in the City of New York | 192,973 | $2.41M | 4.97% | +192,973 | New |
| Harvard Management Co Inc | 289,460 | $3.62M | 0.46% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 448,891 | $5.61M | 0.11% | +37,700+9.2% | Added |
| Rock Springs Capital Management LP | 471,958 | $5.90M | 0.14% | 00.0% | Unchanged |
| Pivotal bioVenture Partners Investment Advisor LLC | 560,595 | $7.01M | 3.05% | 00.0% | Unchanged |
| Cormorant Asset Management, LP | 616,786 | $7.71M | 0.52% | 00.0% | Unchanged |
| Vanguard Group Inc | 737,013 | $9.21M | 0.00% | +371,587+101.7% | Added |
| BVF Inc | 1,813,633 | $22.7M | 0.96% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 2,052,010 | $25.7M | 0.53% | −2,784−0.1% | Reduced |
| Deep Track Capital, LP | 2,104,174 | $26.3M | 1.15% | −259,014−11.0% | Reduced |
| Citadel Advisors LLC | 2,163,916 | $27.0M | 0.03% | −2,551−0.1% | Reduced |
| Artal Group S.A. | 2,243,352 | $28.0M | 1.62% | −42,222−1.8% | Reduced |
| Northpond Ventures, LLC | 4,214,498 | $52.7M | 28.58% | 00.0% | Unchanged |
| Atlas Venture Life Science Advisors, LLC | 5,836,874 | $73.0M | 8.79% | 00.0% | Unchanged |
| Coppell Advisory Solutions LLC | 300 | – | – | +300 | New |
| Coppell Advisory Solutions Corp. | 300 | – | – | +300 | New |
| Ergoteles LLC | 0 | $0 | 0.00% | −28,533−100.0% | Sold out |
| Adage Capital Partners GP, L.L.C. | 0 | $0 | 0.00% | −22,269−100.0% | Sold out |
| Altium Capital Management LP | 0 | $0 | 0.00% | −15,788−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −2−100.0% | Sold out |